1
|
Gondoin A, Hampe C, Eudes R, Fayolle C, Pierre-Eugène C, Miteva M, Villoutreix BO, Charnay-Pouget F, Aitken DJ, Issad T, Burnol AF. Identification of insulin-sensitizing molecules acting by disrupting the interaction between the Insulin Receptor and Grb14. Sci Rep 2017; 7:16901. [PMID: 29203791 PMCID: PMC5715071 DOI: 10.1038/s41598-017-17122-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 11/22/2017] [Indexed: 01/07/2023] Open
Abstract
Metabolic diseases are characterized by a decreased action of insulin. During the course of the disease, usual treatments frequently fail and patients are finally submitted to insulinotherapy. There is thus a need for innovative therapeutic strategies to improve insulin action. Growth factor receptor-bound protein 14 (Grb14) is a molecular adapter that specifically binds to the activated insulin receptor (IR) and inhibits its tyrosine kinase activity. Molecules disrupting Grb14-IR binding are therefore potential insulin-sensitizing agents. We used Structure-Based Virtual Ligand Screening to generate a list of 1000 molecules predicted to hinder Grb14-IR binding. Using an acellular bioluminescence resonance energy transfer (BRET) assay, we identified, out of these 1000 molecules, 3 compounds that inhibited Grb14-IR interaction. Their inhibitory effect on insulin-induced Grb14-IR interaction was confirmed in co-immunoprecipitation experiments. The more efficient molecule (C8) was further characterized. C8 increased downstream Ras-Raf and PI3-kinase insulin signaling, as shown by BRET experiments in living cells. Moreover, C8 regulated the expression of insulin target genes in mouse primary hepatocytes. These results indicate that C8, by reducing Grb14-IR interaction, increases insulin signalling. The use of C8 as a lead compound should allow for the development of new molecules of potential therapeutic interest for the treatment of diabetes.
Collapse
Affiliation(s)
- Anaïs Gondoin
- Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France.,INSERM, U1016, Paris, France
| | - Cornelia Hampe
- Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France.,INSERM, U1016, Paris, France
| | - Richard Eudes
- Université Paris Diderot, Sorbonne-Paris-Cité, Inserm UMR-S 973, Molécules Thérapeutiques in silico, Paris, France
| | - Cyril Fayolle
- Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France.,INSERM, U1016, Paris, France
| | - Cécile Pierre-Eugène
- Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France.,INSERM, U1016, Paris, France
| | - Maria Miteva
- Université Paris Diderot, Sorbonne-Paris-Cité, Inserm UMR-S 973, Molécules Thérapeutiques in silico, Paris, France
| | - Bruno O Villoutreix
- Université Paris Diderot, Sorbonne-Paris-Cité, Inserm UMR-S 973, Molécules Thérapeutiques in silico, Paris, France
| | - Florence Charnay-Pouget
- CP3A Organic Synthesis Group, ICMMO, UMR 8182, CNRS, Université Paris Sud, Université Paris Saclay, Orsay, France
| | - David J Aitken
- CP3A Organic Synthesis Group, ICMMO, UMR 8182, CNRS, Université Paris Sud, Université Paris Saclay, Orsay, France
| | - Tarik Issad
- Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France. .,INSERM, U1016, Paris, France.
| | - Anne-Françoise Burnol
- Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France. .,INSERM, U1016, Paris, France.
| |
Collapse
|
2
|
Pagesy P, Fardini Y, Nguyen TT, Lohmann M, Pierre-Eugene C, Tennagels N, Issad T. Effect of insulin analogues on phosphatidyl inositol-3 kinase/Akt signalling in INS-1 rat pancreatic derived β-cells. Arch Physiol Biochem 2016; 122:54-60. [PMID: 26707268 DOI: 10.3109/13813455.2015.1125364] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
CONTEXT Insulin analogues are largely used for the treatment of diabetic patients, but concerns have been raised about their mitogenic/anti-apoptotic potential. It is therefore important to evaluate these analogues in different cell systems. OBJECTIVE The aim of this work was to establish the pharmacological profiles of insulin analogues towards PI-3 kinase/Akt pathway in INS-1 β-pancreatic cells. METHODS Bioluminescence Resonance Energy Transfer (BRET), in cell western and caspase 3/7 assays, was used to study the effects of ligands. RESULTS Among the five analogues evaluated, only glargine stimulated PI-3 kinase/Akt pathway with higher efficiency than insulin, whereas glargine's metabolite M1 was less efficient. However, glargine did not show higher anti-apoptotic efficiency than insulin. CONCLUSION Glargine was more efficient than insulin for the activation of PI-3 kinase/Akt pathway, but not for the inhibition of caspase 3/7 activity. Moreover, glargine's metabolite M1 displayed lower efficiency than insulin towards PI-3 kinase/Akt activation and caspase 3/7 inhibition.
Collapse
Affiliation(s)
- Patrick Pagesy
- a Inserm, U1016, Institut Cochin , Paris , France
- b CNRS, UMR8104 , Paris , France
- c Université Paris Descartes, Sorbonne Paris Cité , Paris , France , and
| | - Yann Fardini
- a Inserm, U1016, Institut Cochin , Paris , France
- b CNRS, UMR8104 , Paris , France
- c Université Paris Descartes, Sorbonne Paris Cité , Paris , France , and
| | - Tuyet Thu Nguyen
- a Inserm, U1016, Institut Cochin , Paris , France
- b CNRS, UMR8104 , Paris , France
- c Université Paris Descartes, Sorbonne Paris Cité , Paris , France , and
| | | | - Cécile Pierre-Eugene
- a Inserm, U1016, Institut Cochin , Paris , France
- b CNRS, UMR8104 , Paris , France
- c Université Paris Descartes, Sorbonne Paris Cité , Paris , France , and
| | | | - Tarik Issad
- a Inserm, U1016, Institut Cochin , Paris , France
- b CNRS, UMR8104 , Paris , France
- c Université Paris Descartes, Sorbonne Paris Cité , Paris , France , and
| |
Collapse
|
3
|
Boubekeur S, Boute N, Pagesy P, Zilberfarb V, Christeff N, Issad T. A new highly efficient substrate-trapping mutant of protein tyrosine phosphatase 1B (PTP1B) reveals full autoactivation of the insulin receptor precursor. J Biol Chem 2011; 286:19373-80. [PMID: 21487008 DOI: 10.1074/jbc.m111.222984] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
PTP1B is a protein tyrosine-phosphatase located on the cytosolic side of the endoplasmic reticulum that plays an important role in the regulation of the insulin receptor (IR). Replacement of the conserved Asp-181 by alanine is known to convert PTP1B into a substrate-trapping protein that binds to but cannot dephosphorylate its substrates. In this work, we have studied the effect of an additional mutation (Y46F) on the substrate-trapping efficiency of PTP1B-D181A. We observed that this mutation converts PTP1B-D181A into a highly efficient substrate-trapping mutant, resulting in much higher recovery of tyrosine-phosphorylated proteins coimmunoprecipitated with PTP1B. Bioluminescence resonance energy transfer (BRET) experiments were also performed to compare the dynamics of interaction of the IR with these mutants. Basal BRET, which mainly reflects the interaction of PTP1B with the IR precursor during its biosynthesis in the endoplasmic reticulum, was markedly increased with the PTP1B-D181A-Y46F mutant. In contrast, insulin-induced BRET was markedly reduced with PTP1B-D181A-Y46F. I(125) insulin binding experiments indicated that PTP1B-D181-Y46F reduced the expression of IR at the plasma membrane. Reduced expression at the cell surface was associated with higher amounts of the uncleaved IR precursor in the cell. Moreover, we observed that substantial amounts of the uncleaved IR precursor reached the Tris-phosphorylated, fully activated form in an insulin independent fashion. These results support the notion that PTP1B plays a crucial role in the control of the activity of the IR precursor during its biosynthesis. In addition, this new substrate-trapping mutant may be a valuable tool for the identification of new PTP1B substrates.
Collapse
|
4
|
Huang Q, Acha V, Yow R, Schneider E, Sardar DK, Hornsby PJ. Bioluminescence measurements in mice using a skin window. JOURNAL OF BIOMEDICAL OPTICS 2007; 12:054012. [PMID: 17994900 DOI: 10.1117/1.2795567] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Studies of bioluminescence in living animals, such as cell-based biosensor applications, require measurement of light at different wavelengths, but accurate light measurement is impeded by absorption by tissues at wavelengths<600 nm. We present a novel approach to this problem--the use of a plastic window in the skin/body wall of mice--that permits measurements of light produced by bioluminescent cells transplanted into the kidney. The cells coexpressed firefly luciferase (FLuc), a vasopressin receptor--Renilla luciferase (RLuc) fusion protein, and a GFP2-beta-arrestin2 fusion protein. Following coadministration of two luciferase substrates, native coelenterazine and luciferin, bioluminescence is measured via the window using fiber optics and a photon counter. Light emission from the two different luciferases, FLuc and RLuc, is readily distinguishable using appropriate optical filters. When coelenterazine 400a is administered, bioluminescence resonance energy transfer (BRET) occurs between the RLuc and GFP2 fusion proteins and is detected by the use of suitable filters. Following intraperitoneal injection of vasopressin, there is a marked increase in BRET. When rapid and accurate measurement of light from internal organs is required, rather than spatial imaging of bioluminescence, the combination of skin/body wall window and fiber optic light measurement will be advantageous.
Collapse
Affiliation(s)
- Qin Huang
- University of Texas Health Science Center, Department of Physiology and Sam and Ann Barshop Institute for Longevity and Aging Studies, San Antonio, Texas 78245, USA
| | | | | | | | | | | |
Collapse
|
6
|
Milligan G. Applications of bioluminescence- and fluorescence resonance energy transfer to drug discovery at G protein-coupled receptors. Eur J Pharm Sci 2004; 21:397-405. [PMID: 14998570 DOI: 10.1016/j.ejps.2003.11.010] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2003] [Revised: 11/13/2003] [Accepted: 11/13/2003] [Indexed: 11/22/2022]
Abstract
Bioluminescence (BRET)- and fluorescence resonance energy transfer (FRET) techniques have become integral approaches in studies of protein-protein interactions in living cells. They rely on non-radiative transfer of energy between donor and acceptor species that can be appended to the proteins of interest. These techniques display exquisite dependence on distance and orientation between the energy transfer partners. This means they are well suited to measure both small conformational changes in response to ligand binding between partner proteins that remain within a complex or more extensive translocations of proteins between cellular compartments that occur in response to cellular challenge. Introduction of both energy donor and acceptor into a single polypeptide can also allow the detection of ligand-induced conformational switches in monomeric proteins in the millisecond time scale. Many of these approaches are amenable to high throughput screening and the drug discovery process. G protein-coupled receptors (GPCRs) represent a key drug target class. Specific applications of resonance energy transfer techniques to the identification of ligands for this class of protein are highlighted to illustrate general principles.
Collapse
Affiliation(s)
- Graeme Milligan
- Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, University of Glasgow, Glasgow G12 8QQ, Scotland, UK.
| |
Collapse
|